Screening, assays and proteomics at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
22 organizations at TPD Summit 2026 present work in screening, assays & proteomics: 11 technology and service providers, 10 drug developers and 1 academic, government or non-profit body. Between them they bring 30 presentations to the program. Most represented: Amgen (2 on the program), Protai (2 on the program), C4 Therapeutics (1 on the program). As of Oct 8, 2026.
Format
Top represented
Showing 1–16 of 22 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company with medicines in oncology, inflammation, cardiovascular and bone disease, and induced proximity research. | Chair Wed Oct 28 8:20am Chair’s Opening Remarks Investment, partnering & strategy Talk Wed Oct 28 9:30am Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity? Induced proximity beyond degradation Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 2:15pm GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening Screening, assays & proteomics |
Combines proteomics and AI to discover drug targets, biomarkers and degraders. | Panel Tue Oct 27 3:10pm Talk Wed Oct 28 11:30am Proteomics & AI Platform Maps Degrader-Induced Ternary Complex Diversity to Enable Rational Degrader Design AI & computational designScreening, assays & proteomics Panel Thu Oct 29 10:00am |
C4 Therapeutics Watertown, MA | |
Clinical-stage biotech developing small-molecule targeted protein degraders for cancer. | Chair Tue Oct 27 8:20am Chair’s Opening Remarks Investment, partnering & strategy Panel Tue Oct 27 9:00am Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact Investment, partnering & strategy Talk Thu Oct 29 11:45am |
Drug discovery consultancy advising biotech management teams and investors. | Chair Mon Oct 26 8:50am Chair’s Opening Remarks Degrader discovery & design Panel Mon Oct 26 2:15pm Chair Mon Oct 26 4:15pm Chair’s Closing Remarks Screening, assays & proteomics |
Monte Rosa Therapeutics Boston, MA | |
Clinical-stage biotech developing molecular glue degraders from a proteomics-driven discovery platform, for cancer and immune diseases. | Chair Thu Oct 29 8:50am Chair’s Opening Remarks AI & computational design Talk Thu Oct 29 1:45pm Scaling Proteomics for High-Throughput CRBN Target Discovery Screening, assays & proteomics Chair Thu Oct 29 2:45pm Chair’s Closing Remarks Screening, assays & proteomics |
Evotec Hamburg, Germany | ◇Program Partner |
Drug discovery and development partner with its own molecular glue and degrader platforms and programs, alongside research services. | Talk Tue Oct 27 12:00pm Expanding the Molecular Glue Landscape to Enable Program Generation Across Multiple Therapeutic Areas Degrader discovery & design |
◇Innovation Partner | |
Hit-finding services company offering custom compound libraries, including molecular glue sets, chemistry services and computational design. | Talk Wed Oct 28 3:30pm From Design to Application: A CRBN Molecular Glue Library Derived from In-House & Literature-Validated CRBN Binders Screening, assays & proteomics |
ICE Bioscience Beijing, China | ◇Program Partner |
Integrated drug discovery CRO with biology, DMPK and translational platforms taking programs from target identification to preclinical candidate. | Talk Tue Oct 27 3:10pm Decoding RIPTAC Mechanism of Action: Deep Data Mining & Target-Effector Pair Differentiation in Novel Proximity-Based Therapeutics Induced proximity beyond degradation |
NanoTemper Technologies Munich, Germany | ◇Program Partner |
Makes biophysical instruments for measuring molecular binding, protein stability and ternary complex formation in drug discovery. | Talk Tue Oct 27 4:30pm |
NEOsphere Biotechnologies Martinsried, Germany | ◇Program Partner |
Drug discovery company using high-throughput proteomics to find molecular glue degraders and profile their selectivity, partnering programs with drug developers. | Talk Tue Oct 27 12:00pm A Proteome-Wide Screening Engine Delivering Partner-Ready Molecular Glue Degraders at Scale Screening, assays & proteomics |
Pelago Bioscience Solna, Sweden | ◇Innovation Partner |
Service provider measuring drug–target engagement in cells and tissues with its CETSA technology, now adding chemistry capability. | Talk Tue Oct 27 3:00pm From Binder Discovery to Translational Profiling: CETSA® for Targeted Protein Degradation Screening, assays & proteomics |
TGR BioSciences Adelaide, Australia | ◇Program Partner |
Develops cell-based assay kits, including no-wash immunoassays for signaling and protein interactions; part of Abcam since 2020. | Talk Wed Oct 28 12:00pm |
Discovers molecular glue degraders with a bacteria-based positive selection screening system. | Talk Tue Oct 27 2:30pm From Microbes to Degradation: Developing a b-catenin Degrader – From Bacteria to in-vivo Screening, assays & proteomics |
GSK London, UK | |
Global biopharmaceutical company with vaccines and medicines in infectious disease, HIV, respiratory, immunology and oncology. | Talk Thu Oct 29 12:15pm Molecular Glue Discovery & Validation Using DNA-Encoded Libraries Screening, assays & proteomics |
Biotech using phenotypic screening to develop protein degraders for CNS disorders. | Talk Thu Oct 29 1:45pm |
Serinus Biosciences New York, NY | |
Biotech discovering molecular glues in living cells. | Talk Tue Oct 27 2:40pm Mechanism-Agnostic Molecular Glue Discovery in Living Cells Screening, assays & proteomics |
Instantly find 20 buyers in screening, assays & proteomics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction